Information provided by Theflyonthewall.com
) confirmed a deal to purchase a 70% stake in Sprint
) for about $20 billion.
Shares of Sprint were down fractionally after the details of the previously speculated arrangement were publicized. However, shares of Sprint partner Clearwire
), rose 11% though Sprint CEO Dan Hesse said he would not speculate on what Sprint will do with its new-found financial flexibility.
Shares of Citigroup
) jumped nearly 5% as its third-quarter earnings beat expectations after its write-down of the value of its remaining stake in Smith Barney and some other adjustments were excluded.
) stock is advancing after the company announced initial results from a study of one of its hepatitis C virus, or HCV, combination drugs.
Among the notable gainers in the stock market Monday were Yongye International
), up 17% following its receipt of "going private" proposal at $6.60 per share, and Aegerion Pharmaceuticals
), up 9% after the FDA posted briefing documents for a panel's upcoming review of one of the company's drugs.
Among the noteworthy losers was Delcath Systems
), down over 18% after the FDA accepted the company's New Drug Application for its chemosaturation system and designated the NDA for standard review. Also lower were shares of Amedisys
), down 9% after the company signed a new agreement with Humana
) to provide home health services but under a revised reimbursement scheme from their prior arrangement.